Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
about
Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biologyAntigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymersClinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemiaPrimary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapyCriteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cellsThe Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaGene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaWaldenstrom's macroglobulinemia: Recent advances in biology and therapyTargeting NF-kappaB in Waldenstrom macroglobulinemiaDifferential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregationmicroRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemiaDiagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesRisk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in SwedenThalidomide and rituximab in Waldenstrom macroglobulinemiaReview of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patientsChronic immune stimulation and subsequent Waldenström macroglobulinemiaCharacterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell linemicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemiaUpdate on therapeutic options in Waldenström macroglobulinemiaBing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO)Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia.Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaPhase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaWaldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: my way.Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemiaThe clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.
P2860
Q21198869-4DE6CF28-63C6-4933-B08A-A26F0BCCB202Q24316914-1123363A-887F-4F14-B524-24541D3C0177Q24634360-0AB09112-915E-4C23-B9D5-2550944CA5F5Q24646477-6ACEB9AD-51BF-41D9-9940-79F6D369E782Q24647620-39EA16BC-7BD7-4B73-958B-0841CCDE6A98Q26998884-803C0F47-B2C0-4127-8013-544F51BDA92CQ27027562-20B6624C-47BB-4B71-98C0-EE7B9F337EE5Q27314737-FCEA3B13-A4BC-41AC-920D-9729F430FCE8Q28244041-AABA8877-DF1F-4268-9770-934294378416Q28248800-2115B41E-9735-45FE-90D4-D979781C7F49Q28269017-5D34AAF7-87D2-4749-9051-223A92BDE3CEQ28272373-20F1C5A6-D910-49AD-A227-2D93B174E9ABQ28277343-5859A70B-3376-447F-8020-9A569AFBF923Q28284121-69F9E7EF-BB2C-4B5C-B575-9B3D79EE4614Q28290236-0204D158-F72A-496F-9287-B521C892F083Q28290841-5BAC7D1F-B42A-46DF-AF97-8869D6D6B26DQ28291293-5F42339B-1515-48F5-A448-7D542DCCCA43Q28291793-C0F33FE2-8E73-4449-BFD4-BF39203F8054Q28294893-AEDFB5D2-5A46-41A6-B423-3B4DD5513288Q28301328-25F8675B-ABED-4419-8B1E-44EA508BB986Q28303661-D479ED2B-B9B8-4700-AFDB-A0D7C3E932E6Q28304195-FBC244FE-D42B-4C00-9EFC-6358BBC195A1Q28606841-4F12A925-39AA-48DF-8794-25DD01DC9978Q30848149-93C7EAA3-0B50-4616-B67F-4B943945E378Q33370834-B00D5122-92AA-4BC0-81AA-D43BD3D1AC1DQ33382030-3BA757AB-7D52-4899-9B9A-D233A444BC75Q33388196-394E8180-729F-4E97-9B9D-5D1E30ADD8E3Q33395066-FE5AFEB6-D57E-43D5-B773-BBEC9C1855D1Q33395286-04EB19E3-D78D-410D-9B9E-7F687B032257Q33400780-80D63D9D-9E7F-473E-8B26-ED460CAEE28AQ33402669-676853A7-E6E1-4A46-94C1-A7B6499B6176Q33405096-ADA69C1E-7EAA-47CC-8909-5917EA938871Q33408517-69ADEA8F-1CE7-4051-83B8-9F6838D20F76Q33414529-681484DD-98CC-49D2-B02F-23CBD8CE9F06Q33434251-77E4D3CB-CDCF-408E-A1D1-492C7D132498Q33436642-4C714E4F-19D5-47F3-AF48-C57129A3D258Q33438490-7CF4016E-5441-4C7C-AE9D-2A255AD70E52Q33617237-0AE733DC-4098-472F-A50B-9D1C6F32751AQ33660823-D16ED2EC-BA8F-42D4-A810-D9971CAD6EC0Q33695919-413AF07E-0EA6-4FF3-B5C6-7D3476B806F9
P2860
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@ast
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@en
type
label
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@ast
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@en
prefLabel
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@ast
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@en
P2093
P50
P356
P1433
P1476
Clinicopathological definition ...... ldenstrom's Macroglobulinemia.
@en
P2093
Ayad Al-Katib
Enrica Morra
Gerassimos A Pangalis
Mary L McMaster
Philip R Greipp
Roger G Owen
Steven P Treon
P304
P356
10.1053/SONC.2003.50082
P577
2003-04-01T00:00:00Z